|
|
|
|
| LEADER |
01734nam a2200289 u 4500 |
| 001 |
EB001840088 |
| 003 |
EBX01000000000000001004077 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Recommendations for drug therapies for relapsing-emitting multiple sclerosis
|h Elektronische Ressource
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c October 2013, 2013
|
| 300 |
|
|
|a 1 PDF file (ii, 19 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Multiple Sclerosis, Relapsing-Remitting / drug therapy
|
| 653 |
|
|
|a Immunologic Factors / therapeutic use
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Adjuvants, Immunologic / therapeutic use
|
| 653 |
|
|
|a Immunosuppressive Agents / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH therapeutic review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK361342
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Evidence-informed recommendations were developed by the Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. For patients with relapsing-remitting multiple sclerosis (RRMS), what are the preferred initial pharmacological treatment strategies?2. For patients with RRMS, what are the pharmacological strategies for patients not adequately controlled on initial pharmacotherapy?3. Should combination strategies be considered for treatment of patients with RRMS? If so, what are the appropriate treatment options?
|